Blood-Based Biomarkers: A Forgotten Friend of Hyperacute Ischemic Stroke

Frontiers in Neurology

Xiaoming Wang²  Yang Xiang³  Zhilan Liu⁴  Cui Yang⁵ 

[1] Sichuan Provincial People's Hospital, Chengdu, China;Chinese Academy of Sciences Sichuan Translational Medicine Research Hospital, Chengdu, China;Department of Neurology, Affiliated Hospital of North Sichuan Medical College, Nanchong, China;Department of Neurology, General Hospital of Western Theater Command, Chengdu, China;Institute of Neurology, Sichuan Provincial People's Hospital, University of Electronic Science and Technology of China, Chengdu, China;Key Laboratory of Psychosomatic Medicine, Chinese Academy of Medical Sciences, Chengdu, China;North Sichuan Medical College, Nanchong, China;;Sichuan Provincial Center for Mental Health, Sichuan Academy of Medical Sciences &

关键词: hyperacute ischemic stroke;    blood-based biomarker;    genetic and genomic;    glial activation;    neuronal injury;    oxidative stress;   

DOI  :  10.3389/fneur.2021.634717

来源: DOAJ

【 摘 要 】

Ischemic stroke (IS) is the second leading cause of death worldwide. Multimodal neuroimaging techniques that have significantly facilitated the diagnosis of hyperacute IS are not widely used in underdeveloped areas and community hospitals owing to drawbacks such as high cost and lack of trained operators. Moreover, these methods do not have sufficient resolution to detect changes in the brain at the cellular and molecular levels after IS onset. In contrast, blood-based biomarkers can reflect molecular and biochemical alterations in both normal and pathophysiologic processes including angiogenesis, metabolism, inflammation, oxidative stress, coagulation, thrombosis, glial activation, and neuronal and vascular injury, and can thus provide information complementary to findings from routine examinations and neuroimaging that is useful for diagnosis. In this review, we summarize the current state of knowledge on blood-based biomarkers of hyperacute IS including those associated with neuronal injury, glial activation, inflammation and oxidative stress, vascular injury and angiogenesis, coagulation and thrombosis, and metabolism as well as genetic and genomic biomarkers. Meanwhile, the blood sampling time of the biomarkers which are cited and summarized in the review is within 6 h after the onset of IS. Additionally, we also discuss the diagnostic and prognostic value of blood-based biomarkers in stroke patients, and future directions for their clinical application and development.

【 授权许可】

Unknown